- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03967977
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
December 4, 2023 updated by: BeiGene
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of Either Cisplatin or Carboplatin +Gemcitabine + Tislelizumab Compared With Either Cisplatin or Carboplatin + Gemcitabine + Placebo as First-line Treatment for Patients With Locally Advanced or Metastatic Urothelial Carcinoma
This is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study designed to compare the efficacy and safety of tislelizumab + either cisplatin or carboplatin + gemcitabine versus placebo+ either cisplatin or carboplatin + gemcitabine in approximately 420 participants with locally advanced or metastatic urothelial carcinoma who have not received prior systemic therapy.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
420
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: BeiGene
- Phone Number: +1-877-828-5568
- Email: clinicaltrials@beigene.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100142
- Recruiting
- Beijing Cancer Hospital
-
Beijing, Beijing, China, 100034
- Recruiting
- Peking University First Hospital
-
Beijing, Beijing, China, 100050
- Recruiting
- Beijing Friendship Hospital, Capital Medical University
-
-
Chongqing
-
Chongqing, Chongqing, China, 400030
- Recruiting
- Chongqing Cancer Hospital
-
-
Fujian
-
Quanzhou, Fujian, China, 362001
- Recruiting
- The Second Affiliated Hospital of Fujian Medical University
-
Xiamen, Fujian, China, 361003
- Recruiting
- The First Affiliated Hospital of Xiamen University
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Recruiting
- Zhujiang Hospital of Southern Medical University
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Recruiting
- Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Recruiting
- Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Recruiting
- The First Hospital of Jilin University
-
-
Shanghai
-
Shanghai, Shanghai, China, 200000
- Recruiting
- Fudan University Shanghai Cancer Center
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recruiting
- West China Hospital, Sichuan University
-
-
Tianjin
-
Tianjin, Tianjin, China, 300000
- Recruiting
- The Second Affiliated Hospital of Tianjin Medical University
-
-
Xinjiang
-
Urumqi, Xinjiang, China, 830000
- Recruiting
- Affiliated Cancer Hospital of Xinjiang Medical University
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310014
- Recruiting
- Zhejiang Provincial Peoples Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Male or female aged 18 to 75 years on the day of signing the Informed Consent Form (ICF)
- Histologically confirmed, inoperable, locally advanced, or metastatic urothelial cancer (UC)
- Must be eligible to receive cisplatin or carboplatin in the investigator's judgment
- Have had no prior systemic chemotherapy for locally advanced or metastatic UC
- Must be able to provide fresh or archival tumor tissues with an associated pathological report.
- Must have evaluable disease (either measurable or non-measurable) as defined per RECIST v1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.
- Adequate organ function before randomization:
Key Exclusion Criteria:
- Received prior therapies targeting PD-1, PD-L1, PD-L2, CTLA4, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
- Any approved anticancer therapy within 28 days before randomization.
- Active leptomeningeal disease or uncontrolled, untreated brain metastasis
- Participants with uncontrolled hypercalcemia
- Participants with active autoimmune diseases or history of autoimmune diseases that may relapse
- History of interstitial lung disease, noninfectious pneumonitis, or uncontrolled diseases
- A known history of HIV infection.
- Prior allogeneic stem cell transplantation or organ transplantation.
- History of severe hypersensitivity reactions to other monoclonal antibodies. 10.History of allergic reactions to cisplatin, carboplatin, or other platinum-containing compounds.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Tislelizumab in combination with chemotherapy
Tislelizumab: Day 1 of each 21-day cycle, to be administered until Progressive Disease or intolerable toxicity Cisplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Carboplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Gemcitabine: Days 1 and 8 of each 21-day cycle, to be administered up to 6 cycles
|
200 mg administered Intravenously (IV) as specified in the treatment arm
Other Names:
70 mg/m2 administered IV as specified in the treatment arm
1000 mg/m2 administered IV as specified in the treatment arm
Area Under the Curve (AUC) 4.5 administered IV as specified in the treatment arm
|
Placebo Comparator: Placebo in combination with chemotherapy
Placebo: Day 1 of each 21-day cycle, to be administered until Progressive Disease or intolerable toxicity Cisplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Carboplatin: Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Gemcitabine: Days 1 and 8 of each 21-day cycle, to be administered up to 6 cycles
|
70 mg/m2 administered IV as specified in the treatment arm
1000 mg/m2 administered IV as specified in the treatment arm
Area Under the Curve (AUC) 4.5 administered IV as specified in the treatment arm
Tislelizumab placebo to match
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival (OS) in the Intent to Treat (ITT) set
Time Frame: From first randomization up to 3.5 years, approximately
|
From first randomization up to 3.5 years, approximately
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR) per RECIST v1.1 in ITT
Time Frame: From first randomization up to 3.5 years, approximately
|
the proportion of participants who had Complete Response (CR) or Partial Response (PR) as assessed by the investigator per RECIST v1.1 in the ITT Analysis Set
|
From first randomization up to 3.5 years, approximately
|
Duration of response (DOR)
Time Frame: From first randomization up to 3.5 years, approximately
|
the time from the first occurrence of a documented objective response to documented Progressive Disease (PD), or death from any cause, whichever occurs first, as determined by the investigator per RECIST v1.1 in the ITT Analysis Set
|
From first randomization up to 3.5 years, approximately
|
Progression-free survival (PFS)
Time Frame: From first randomization up to 3.5 years, approximately
|
the time from randomization to the first objectively documented PD, or death from any cause, whichever occurs first, as determined by the investigator per RECIST v1.1 in the ITT Analysis Set
|
From first randomization up to 3.5 years, approximately
|
Overall survival rate at 1 and 2 years for each treatment arm
Time Frame: From first randomization up to 3.5 years, approximately
|
the proportion of OS participants at 1 year and 2 years from randomization in the ITT Analysis Set
|
From first randomization up to 3.5 years, approximately
|
Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life-Core 30(EORTC QLQC30)
Time Frame: From first randomization up to 3.5 years, approximately
|
1) to assess overall health status/Quality of Life with 2 questions which are with range from minimum score 1 as worse outcome and maximum score 7 as higher values represent a better 2) to assess quality of life with 28 questions about Physical functioning, emotional functioning, social functioning etc. which are with range from minimum scores 1 representing as better to maximum scores 4 as worse outcome.
|
From first randomization up to 3.5 years, approximately
|
Incidence and severity of treatment-emergent adverse events (AEs)
Time Frame: From first randomization up to 3.5years, approximately
|
Incidence and severity of treatment-emergent adverse events (AEs) graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)v5.0
|
From first randomization up to 3.5years, approximately
|
Change from baseline in European Quality of Life 5-Dimension, 5-Level version (EQ-5D-5L)
Time Frame: From first randomization up to 3.5 years, approximately
|
to assess health status with 1) 5 questions about Mobility, Self-Care, Usual activities, Pain/Discomfort, Anxiety/Depression which are with 5 options.
2) one question about health status at the day of completing the questionnaire with range from minimum score 0 as worse outcome to maximum scores 100 as higher values represent as better.
|
From first randomization up to 3.5 years, approximately
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Dingwei Ye, MD, Fudan University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 29, 2019
Primary Completion (Estimated)
January 1, 2024
Study Completion (Estimated)
January 1, 2024
Study Registration Dates
First Submitted
May 23, 2019
First Submitted That Met QC Criteria
May 27, 2019
First Posted (Actual)
May 30, 2019
Study Record Updates
Last Update Posted (Actual)
December 5, 2023
Last Update Submitted That Met QC Criteria
December 4, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Carcinoma
- Carcinoma, Transitional Cell
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Carboplatin
- Gemcitabine
- Tislelizumab
Other Study ID Numbers
- BGB-A317-310
- CTR20190543 (Registry Identifier: Center for drug evaluation, CFDA)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urothelial Carcinoma
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States
-
University of UtahNational Cancer Institute (NCI)RecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Urothelial Carcinoma, Sarcomatoid VariantUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Locally Advanced Urothelial Carcinoma | Recurrent Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Advanced Urothelial CarcinomaUnited States
-
Mamta ParikhNational Cancer Institute (NCI); Karyopharm Therapeutics IncRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial CarcinomaUnited States
-
Emory UniversityNational Cancer Institute (NCI); ExelixisRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma With Squamous DifferentiationUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Urothelial Carcinoma | Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant | Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant | Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation | Infiltrating Bladder Urothelial Carcinoma With Squamous... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Metastatic Renal Pelvis and Ureter Urothelial CarcinomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage II Bladder Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma | Stage 0is Bladder Urothelial Carcinoma | Stage I Bladder Urothelial CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnInfiltrating Bladder Urothelial Carcinoma | Stage II Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma | Stage III Bladder Urothelial CarcinomaUnited States
Clinical Trials on Tislelizumab
-
Peking University Cancer Hospital & InstituteRecruitingNon-small Cell Lung Cancer | Consolidation Immunotherapy | Radiotherapy or Sequential ChemoradiationChina
-
Jiangsu Yahong Meditech Co., Ltd aka AsierisRecruitingMuscle Invasive Bladder CancerUnited States, China
-
Fudan UniversityActive, not recruitingHepatocellular CarcinomaChina
-
Henan Cancer HospitalNot yet recruiting
-
Shanghai Gopherwood Biotech Co., Ltd.RecruitingAdvanced Solid TumorChina
-
GeneScience Pharmaceuticals Co., Ltd.RecruitingMalignant Solid TumorsChina
-
Fudan UniversityRecruitingRefractory Malignant AscitesChina
-
Peter MacCallum Cancer Centre, AustraliaRecruiting
-
Peking UniversityRecruitingGastric Cancer | Colo-rectal CancerChina
-
Fudan UniversityNot yet recruiting